February 26, 2018
Authored and Edited by Bonnie Fletcher Price, Ph.D.; Thomas L. Irving
In Momenta Pharmaceuticals, Inc. et al. v. Amphastar Pharmaceuticals, Inc. et al., No. 11-cv-11681 (D. Mass. 2018), the District Court of Massachusetts found that Momenta waived by implication the right to enforce its patent by failing to disclose the patent application while participating in a USP advisory panel.
The USP advisory panel chose USP <207> as the official test to determine whether enoxaparin products conform to the structure dictated in the USP monograph. The court found that regardless of Momenta’s opposition to USP <207>, it had a duty to disclose to the USP that its application potentially covered USP <207>. Because the court found that Momenta breached this duty, the court also found that Momenta had waived the right to enforce its patent with respect to methods that comply with USP <207>. However, the court found that Momenta had not waived its right to enforce the patent with respect to methods that do not comply with USP <207>.
drugs, Food and Drug Administration (FDA), District Court, District of Massachusetts, new drug application (NDA), generic drug, infringement
Copyright © 2018 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
June 10-12, 2024
San Francisco
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
Webinar
May 9, 2024
Webinar
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.